Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital SolutionsCAMBRIDGE, Mass., October 9, 2024-- Flagship Pioneering, the bioplatform innovation company, today announced that Paul Parker has joined as Managing Partner, Capital Solutions and Value Realization.

旗舰先锋宣布任命保罗·帕克（Paul Parker）为领先资本解决方案管理合伙人马萨诸塞州剑桥市，2024年10月9日——旗舰先锋生物平台创新公司今天宣布，保罗·帕克（Paul Parker）已加入成为资本解决方案和价值实现管理合伙人。

In this role, Parker will lead all capital solutions efforts at Flagship, driving portfolio value realization, fundraising activities, and building and managing Flagship's relationships with Limited Partners as well as strategic and financial investors. He will also play a key role on Flagship's senior leadership team, helping drive value, impact, and effectiveness across the organization..

在这个职位上，Parker将领导旗舰公司的所有资本解决方案工作，推动投资组合价值实现、筹资活动，并建立和管理旗舰公司与有限合伙人以及战略和金融投资者的关系。他还将在旗舰公司的高级领导团队中发挥关键作用，帮助推动整个组织的价值、影响力和有效性。。

Parker brings over 35 years of experience in banking, pharma and biotech, as well as in mergers and acquisitions (M&A), corporate strategy and organizational leadership. He has worked across multiple sectors and geographies, built and managed several multi-billion-dollar businesses, and led teams of several thousand employees.

帕克在银行、制药和生物技术以及并购（M＆A）、公司战略和组织领导方面拥有35年以上的经验。他曾在多个部门和地区工作，建立和管理了数十亿美元的业务，并领导了数千名员工的团队。

He previously served as Co-Chairman of the Global M&A Group for Goldman Sachs & Co., Chairman and Head of Global M&A and Co-Head of Corporate Finance at Barclays Group Plc, and Chairman and Head of Global M&A at Lehman Brothers..

他曾担任高盛集团全球并购集团联席主席、巴克莱集团董事长兼全球并购负责人、公司财务联席负责人，以及雷曼兄弟董事长兼全球并购负责人。。

Parker becomes Flagship's third Managing Partner, alongside Doug Cole and Stephen Berenson, as the company enters its next phase of growth and development following the raise of its latest capital pool of $3.6B in July of this year. Most recently, he served as a Corporate Officer and held the role of Senior Vice President, Strategy and Corporate Development at Thermo Fisher Scientific which comprised a number of enterprise-level operating roles, including being a member of the leadership team, as well as having responsibility for Corporate Strategy, Corporate Development, Strategic Capital, Integration Management, Corporate Social Responsibility, and Government Relations..

帕克成为旗舰公司的第三任管理合伙人，与道格·科尔（DougCole）和斯蒂芬·贝伦森（StephenBerenson）一道，该公司在今年7月筹集了36亿美元的最新资金后，进入了下一个增长和发展阶段。最近，他担任公司高管，并担任Thermo Fisher Scientific战略与公司发展高级副总裁，其中包括多个企业级运营角色，包括领导团队成员，以及负责公司战略、公司发展、战略资本、整合管理、公司社会责任和政府关系。。

'At Flagship, we found, build and create companies for two reasons: to better the health of people and the planet, and to grow and realize value for investors and partners,' said Noubar Afeyan, Founder and CEO of Flagship Pioneering. 'Paul's extensive acumen with banking and investing across both biotech and pharma, alongside his track record of corporate leadership, will be a huge advantage to us in realizing those goals.'.

旗舰创业公司创始人兼首席执行官努巴尔·阿费扬（Noubar Afeyan）说：“在旗舰公司，我们发现、建立和创建公司有两个原因：改善人类和地球的健康，为投资者和合作伙伴增长和实现价值。保罗在生物技术和制药领域在银行和投资方面的广泛敏锐，以及他在企业领导方面的良好记录，将为我们实现这些目标带来巨大优势。”。

'I've had the privilege of working with Noubar and other members of the Flagship leadership team in various roles over the years, and I am consistently impressed by Flagship's distinctive approach to company and bioplatform creation,' said Paul Parker. 'I look forward to bringing my experience in helping businesses build and realize value to Flagship where, with my colleagues, we can enable our companies to improve health and sustainability and deliver exceptional results for our investors.'.

保罗·帕克（PaulParker）说：“多年来，我有幸与努巴尔（Noubar）和旗舰领导团队的其他成员一起担任各种角色，旗舰公司独特的公司和生物平台创建方法一直给我留下深刻印象。”我期待着将我在帮助企业建立和实现价值方面的经验带到旗舰店，与我的同事一起，我们可以使我们的公司改善健康和可持续性，并为我们的投资者带来非凡的成果。”。

About Paul Parker

Paul Parker is an experienced executive and over his career he has worked across multiple sectors and geographies, built and managed several multi-billion-dollar businesses, and led teams of several thousand employees. He brings over 35 years of experience in the life sciences industry in both banking, including pharma and biotech, as well as in mergers and acquisitions (M&A), corporate strategy and organizational leadership..

。他在生命科学行业拥有超过35年的经验，涉及银行业，包括制药和生物技术，以及并购（M＆A），公司战略和组织领导。。

Prior to joining Flagship, Parker was a Corporate Officer, member of the Company Leadership Team, and served as Senior Vice President, Strategy and Corporate Development for Thermo Fisher Scientific. In this capacity he held a number of enterprise-level operating roles, including having responsibility for Corporate Strategy, Corporate Development, Strategic Capital, Integration Management, Corporate Social Responsibility, and Government Relations.

在加入Flagship之前，Parker是公司高管、公司领导团队成员，曾担任Thermo Fisher Scientific战略和公司发展高级副总裁。在这个职位上，他担任了许多企业级的运营角色，包括负责企业战略、企业发展、战略资本、整合管理、企业社会责任和政府关系。

He previously served as Co-Chairman of the Global Mergers and Acquisitions Group for Goldman Sachs & Co. and served on the firm's Partnership Committee and the Investment Banking Senior Leadership Council. Prior to Goldman Sachs, Parker held senior positions at Barclays Group Plc where he served as Chairman and Head of Global M&A, subsequently adding responsibilities as Co-Head of Corporate Finance.

。在加入高盛之前，帕克曾在巴克莱集团（Barclays Group Plc）担任高级职位，担任董事长兼全球并购主管，随后又担任公司财务联席主管。

He was previously an investment banker at Lehman Brothers in several senior leadership positions, ultimately serving as Chairman and Head of Global M&A. Earlier in his career, Parker held positions at other financial institutions, including J.P. Morgan & Co..

他曾担任雷曼兄弟（LehmanBrothers）的几位高级领导职位的投资银行家，最终担任全球并购的主席和负责人。在他职业生涯的早期，帕克曾在其他金融机构任职，包括摩根大通（J.P.Morgan&Co.）。。

Parker is currently a Board member of the Clorox Company, where he has served for the past four years.

帕克目前是Clorox公司的董事会成员，他在该公司工作了四年。

He earned an MBA with distinction from Harvard Business School and a bachelor's degree in international studies from the University of North Carolina at Chapel Hill.

他以优异的成绩获得了哈佛商学院的MBA学位，并获得了北卡罗来纳大学教堂山分校的国际研究学士学位。

For more, watch 'Three Questions with Paul Parker' to hear about his journey from banking to biotech and what drew him to Flagship.

更多信息，请观看《与保罗·帕克的三个问题》，了解他从银行业到生物技术的历程，以及是什么吸引他来到旗舰公司。

About Flagship Pioneering

关于旗舰先锋

Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value.

旗舰先锋发明并建立生物平台公司，每个公司都有潜力开发多种产品，改变人类健康或可持续发展。自2000年推出以来，Flagship已经发起并培育了100多家科学企业，总价值超过750亿美元。

Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises 43 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.Contact: .

截至2024年7月宣布的最新融资，旗舰公司的经营管理资产为140亿美元。目前的旗舰生态系统由43家公司组成，包括Foghorn Therapeutics（纳斯达克：FHTX），Moderna（纳斯达克：MRNA），Omega Therapeutics（纳斯达克：OMGA），Sana Biotechnology（纳斯达克：Sana），Generate Biomedicines，Inari，Indigo Agriculture和Tessera Therapeutics。联系人：。。

Media Contact

媒体联系人

press@flagshippioneering.com

press@flagshippioneering.com